Literature DB >> 19563804

Evaluation of Toxoplasma gondii placental transmission in BALB/c mice model.

Sandia B Pezerico1, Helio Langoni, Aristeu V Da Silva, Rodrigo C Da Silva.   

Abstract

Toxoplasma gondii infection is common worldwide and highly important to pregnant women as it can be transmitted to the fetus via the placenta. This study aimed at evaluating the prevention of placental transmission in two different strains after chronic infection with each one of the strains. A BALB/c mice model was inoculated 30days before breeding (immunization) and re-infected 12 and 15days after pregnancy (challenge). Seven experimental groups were assayed: G1: ME49-immunization (type II), M7741-challenge (type III); G2: M7741-immunization, ME49-challenge; G3, ME49-immunization; G4: M7741-immunization; G5: ME49-challenge; G6: M7741-challenge; G7: saline solution inoculation. Serology, mouse bioassay, PCR and RLFP of the uterus, placenta and fetus were performed to determine the congenital transmission of the strains challenged after chronic infection. IgG T. gondii antibodies were detected in G1, G2, G3 and G4, but not in G5, G6 and G7. All animals of G5 and G6 were IgM-positive. Congenital infection was not detected by bioassay and PCR. Nonetheless, placentas from G3 and G4 resulted positive but no corresponding fetal infection was detected. G1 and G2 did not show the genotype of the strain challenged during pregnancy, only those of chronic infection. Thus, the chronically infected BALB/c mice showed no re-infection after inoculation with another strain during pregnancy. Further studies with different parasite loads and different mice lineages are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563804     DOI: 10.1016/j.exppara.2009.06.015

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  7 in total

1.  Tissue barriers of the human placenta to infection with Toxoplasma gondii.

Authors:  Jennifer R Robbins; Varvara B Zeldovich; Anna Poukchanski; John C Boothroyd; Anna I Bakardjiev
Journal:  Infect Immun       Date:  2011-11-14       Impact factor: 3.441

Review 2.  Microbial Vertical Transmission during Human Pregnancy.

Authors:  Nitin Arora; Yoel Sadovsky; Terence S Dermody; Carolyn B Coyne
Journal:  Cell Host Microbe       Date:  2017-05-10       Impact factor: 21.023

3.  Spread and genotype of Toxoplasma gondii in naturally infected alpine chamois (Rupicapra r. rupicapra).

Authors:  Nicoletta Formenti; Alessandra Gaffuri; Tiziana Trogu; Roberto Viganò; Nicola Ferrari; Paolo Lanfranchi
Journal:  Parasitol Res       Date:  2016-03-10       Impact factor: 2.289

4.  Calomys callosus chronically infected by Toxoplasma gondii clonal type II strain and reinfected by Brazilian strains is not able to prevent vertical transmission.

Authors:  Priscila S Franco; Neide M da Silva; Bellisa de Freitas Barbosa; Angelica de Oliveira Gomes; Francesca Ietta; E K Shwab; Chunlei Su; José R Mineo; Eloisa A V Ferro
Journal:  Front Microbiol       Date:  2015-03-10       Impact factor: 5.640

5.  Toxoplasmosis: Experimental Vaginal Infection in NMRI Mice and Its Effect on Uterin, Placenta and Fetus Tissues.

Authors:  Parvin Dokt Bayat; Zahra Eslamirad; Saeedeh Shojaee
Journal:  Iran Red Crescent Med J       Date:  2013-07-05       Impact factor: 0.611

Review 6.  Do the placental barrier, parasite genotype and Toll-like receptor polymorphisms contribute to the course of primary infection with various Toxoplasma gondii genotypes in pregnant women?

Authors:  W Wujcicka; J Wilczyński; D Nowakowska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-30       Impact factor: 3.267

Review 7.  Calomys callosus: An Experimental Animal Model Applied to Parasitic Diseases Investigations of Public Health Concern.

Authors:  Rafael Borges Rosa; Mylla Spirandelli da Costa; Samuel Cota Teixeira; Emilene Ferreira de Castro; Willyenne Marília Dantas; Eloisa Amália Vieira Ferro; Murilo Vieira da Silva
Journal:  Pathogens       Date:  2022-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.